1-甲基-5-吡啶-3-基-1H-咪唑-2-硫醇 | 51941-16-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-甲基-5-吡啶-3-基-1H-咪唑-2-硫醇
• 英文名称: 1-Methyl-2-mercapto-5-(3'-pyridyl)-imidazol
• 英文别名: 1-methyl-5-pyridin-3-yl-1,3-dihydro-imidazole-2-thione；1-Methyl-2-mercapto-5-(3-pyridyl)imidazole；3-methyl-4-pyridin-3-yl-1H-imidazole-2-thione
• CAS: 51941-16-3
• 化学式: C₉H₉N₃S
• 分子量: 191.257
• InChiKey: DEUPXTPWWLUQRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  31.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (1S,5R)-3-(3-chloropropyl)-1-[4-(trif luoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane 、 1-甲基-5-吡啶-3-基-1H-咪唑-2-硫醇 生成 (1S,5R)-3-(3-[{1-methyl-5-(3-pyridinyl)-1H-imidazol-2-yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
  参考文献：
  名称：

  AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS

  摘要：

  本文所披露的化合物具有公式（I），其中G和Q是杂环芳基基团。这些化合物对于治疗精神病或精神病状况、物质滥用、早泄或认知障碍有用。

  公开号：

  US20090326011A1

文献信息

• Compositions and methods for the prevention and treatment of circulatory conditions
  申请人：Lau T. David

  公开号：US20070037756A1

  公开（公告）日：2007-02-15

  The present invention relates to compositions and the prevention and treatment of circulatory conditions. In one embodiment, the present invention contemplates a compositions comprising anti-platelet aggregating activity. In another embodiment, the present invention contemplates methods to prevent or treat vascular or cardiovascular diseases. In another embodiment, the present invention relates to a method to prevent or treat cardiovascular disease by administering a glycerol saccharide derivative, an arylpolyphenol, a saccharide substituted with an arylpolyphenol, or a steroid substituted with an arylpolyphenol capable of reducing platelet aggregation. In one embodiment, the invention relates to a method of using the compounds capable of reducing platelet aggregation in order to prevent the recurrence of a heart attack by administration of the compounds to a subject after the subject has experienced a heart attack.

  本发明涉及组合物及其在循环疾病的预防和治疗中的应用。在一种实施例中，本发明涉及一种包含抗血小板聚集活性的组合物。在另一种实施例中，本发明涉及预防或治疗血管或心血管疾病的方法。在另一种实施例中，本发明涉及通过给予一种能够减少血小板聚集的甘油糖衍生物、芳基多酚、被芳基多酚取代的糖或被芳基多酚取代的类固醇来预防或治疗心血管疾病的方法。在一种实施例中，本发明涉及使用能够减少血小板聚集的化合物的方法，以通过给予化合物来预防心脏病发作的再次发生，该化合物在主体经历心脏病发作后给予。
• AZABICYCLO[3.1.0]HEXANE DERIVAIVES AS DOPAMIN D3 RECEPTOR MODULATORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1891057B1

  公开（公告）日：2010-10-27
• Sulfated Galactans With Antithrombotic Activity, Pharmaceutical Composition, Method for Treating or Prophylaxis of Arterial or Venous Thrombosis, Method of Extraction and Use Thereof
  申请人：Mourão Paulo Antonio de Souza

  公开号：US20110263527A1

  公开（公告）日：2011-10-27

  The present invention relates to low molecular weight sulfated galactans, obtained from algae, particularly genus Botryocladia, preferably species Botryocladia occidentallis, which have no effect on the factor XII activation of the clotting cascade, having antithrombotic heparinoid activity. The present invention also refers to a pharmaceutical composition comprising said sulfated galactans and the use thereof, as heparin substitute, in the treatment or prophylaxis of arterial or venous thrombosis in humans and animals. Furthermore, the present invention provides a method of extraction of the said sulfated galactans.
• [EN] AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE L'AZA-BICYCLO[3 . 1 . 0]HEXANE COMME MODULATEURS DU RÉCEPTEUR D3 DE LA DOPAMINE
  申请人：GLAXO GROUP LTD

  公开号：WO2006133946A1

  公开（公告）日：2006-12-21

  [EN] The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: (I), processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D₃ receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.
  [FR] La présente invention concerne de nouveaux composés de formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci : (I), des procédés pour leur préparation, des intermédiaires utilisés dans ces procédés, des compositions pharmaceutiques qui les comprennent et leur utilisation en thérapie, comme modulateurs des récepteurs D3 de la dopamine, par. ex., pour traiter la dépendance aux médicaments, comme agents antipsychotiques pour traiter des troubles du spectre obsessionnel-compulsif, des problèmes d'éjaculation précoce ou une déficience intellectuelle.